Inhibikase Therapeutics, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Policy Regarding Timing of Awards of Options and Other Option-Like Instruments

We provide the following discussion of the timing of stock appreciation rights awards in relation to the disclosure of material nonpublic information, as required by Item 402(x) of Regulation S-K. Our Board of Directors generally grants annual equity awards, including stock option grants to our named executive officers, in the first quarter of each fiscal year. In addition, new hires receive stock option grants at the time of their hiring.

Our Board of Directors approved the stock option awards to Dr. Werner and Mr. Lees-Rolfe on April 1, 2024. The grant to Mr. Lees-Rolfe was made in connection with the compensation arrangement related to his appointment as Chief Financial Officer, which was announced pursuant to the filing of a Current Report on Form 8-K/A on April 2, 2024. In accordance with the requirements of the SEC, the following table discloses additional information with respect to the stock options that we awarded to Dr. Werner and Mr. Lees-Rolfe on April 1, 2024.

In addition, our Board of Directors approved the stock options awards to Dr. Werner and Mr. Lees-Rolfe on October 9, 2024, which were granted in connection with the private placement financing transaction that was announced that same day pursuant to a filing of a Current Report on Form 8-K. Certain of such stock option awards were granted (i) with an exercise price at a premium to the market price and (ii) will only be exercisable following the expiration of the exercise period of the Series A-1 Warrants and Series B-1 Warrants in the same proportions as the Series A-1 Warrants and Series B-1 Warrants, as applicable, are actually exercised. In accordance with the requirements of the SEC, the following table discloses additional information with respect to the stock options that we awarded to Dr. Werner and Mr. Lees-Rolfe on October 9, 2024.

Our Board of Directors did not take material nonpublic information into account when determining the timing or terms of these awards. The grant date was selected based on the date on which our Board of Directors finalized and approved the awards.


Name	Grant Date	Number of Securities Underlying the Award		Exercise Price of the Award			Grant Date Fair Value of the Award(1)		Percentage change in the closing market price of the securities underlying the award between the trading day ending immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following the disclosure of material nonpublic information
Milton H. Werner, Ph.D.	4/1/2024		45,000	$	2.16	(2)	$	70,366	0.5%
	10/9/2024		5,315,056	$	1.26		$	5,322,601	9.2%, 16.7%(3)
	10/9/2024		2,207,671	$	1.45		$	1,744,088	9.2%, 16.7%(3)
	10/9/2024		4,059,744	$	1.58		$	3,044,808	9.2%, 16.7%(3)
Garth Lees-Rolfe	4/1/2024		90,000	$	2.16	(2)	$	140,732	0.5%
	10/9/2024		470,861	$	1.26		$	471,529	9.2%, 16.7%(3)
	10/9/2024		235,383	$	1.45		$	185,956	9.2%, 16.7%(3)
	10/9/2024		432,853	$	1.58		$	324,640	9.2%, 16.7%(3)

(1) The amount reported in this column reflects the grant date fair value of the stock options as determined under the principles used to calculate the grant date fair value of equity awards for purposes of our financial statements in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718. For a discussion of the assumptions

and methodologies used to value the award, please see the discussion of option awards contained in the notes to the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 27, 2025.

(2) On October 9, 2024, the Board of Directors approved the repricing of these stock options to $1.26, subject to approval by our stockholders, which was attained on January 3, 2025. For a discussion of the repricing, see below under “Executive Compensation—Executive Equity Compensation.”

(3) We filed a current report on Form 8-K on October 9, 2024 and a separate current report on Form 8-K on October 10, 2024. The percentage change in the closing market price of the securities underlying the award between the trading day ending immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following the disclosure of material nonpublic information for each of these dates was 9.2% and 16.7%, respectively.

Award Timing Predetermined

true

Awards Close in Time to MNPI Disclosures, Table


Name	Grant Date	Number of Securities Underlying the Award		Exercise Price of the Award			Grant Date Fair Value of the Award(1)		Percentage change in the closing market price of the securities underlying the award between the trading day ending immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following the disclosure of material nonpublic information
Milton H. Werner, Ph.D.	4/1/2024		45,000	$	2.16	(2)	$	70,366	0.5%
	10/9/2024		5,315,056	$	1.26		$	5,322,601	9.2%, 16.7%(3)
	10/9/2024		2,207,671	$	1.45		$	1,744,088	9.2%, 16.7%(3)
	10/9/2024		4,059,744	$	1.58		$	3,044,808	9.2%, 16.7%(3)
Garth Lees-Rolfe	4/1/2024		90,000	$	2.16	(2)	$	140,732	0.5%
	10/9/2024		470,861	$	1.26		$	471,529	9.2%, 16.7%(3)
	10/9/2024		235,383	$	1.45		$	185,956	9.2%, 16.7%(3)
	10/9/2024		432,853	$	1.58		$	324,640	9.2%, 16.7%(3)

(1) The amount reported in this column reflects the grant date fair value of the stock options as determined under the principles used to calculate the grant date fair value of equity awards for purposes of our financial statements in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718. For a discussion of the assumptions

and methodologies used to value the award, please see the discussion of option awards contained in the notes to the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 27, 2025.

(2) On October 9, 2024, the Board of Directors approved the repricing of these stock options to $1.26, subject to approval by our stockholders, which was attained on January 3, 2025. For a discussion of the repricing, see below under “Executive Compensation—Executive Equity Compensation.”

(3) We filed a current report on Form 8-K on October 9, 2024 and a separate current report on Form 8-K on October 10, 2024. The percentage change in the closing market price of the securities underlying the award between the trading day ending immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following the disclosure of material nonpublic information for each of these dates was 9.2% and 16.7%, respectively.